Daclizumab

In the US, Daclizumab (daclizumab systemic) is a member of the drug class interleukin inhibitors and is used to treat Organ Transplant - Rejection Prophylaxis and Rheumatoid Arthritis.

US matches:

• Daclizumab


• Daclizumab Intravenous

Scheme

Rec.INN

ATC (Anatomical Therapeutic Chemical Classification)

L04AA08,L04AC01

CAS registry number (Chemical Abstracts Service)

0152923-56-3

Chemical Formula

C6394-H9888-N1696-O2012-S44

Molecular Weight

144129

Therapeutic Category

Immunosuppressant

Chemical Name

Immunoglobulin G 1 (human-mouse monoclonal clone 1H4 þ-chain anti-human interleukin 2 receptor), disulfide with human-mouse monoclonal clone 1H4 light chain, dimer

Foreign Names

• Daclizumabum (Latin)
• Daclizumab (German)
• Daclizumab (French)
• Daclizumab (Spanish)

Generic Names

• Daclizumab (OS: USAN, BAN, DCF)
• Ro 24-7375 (IS)

Brand Names

• Zenapax
  Roche, Argentina; Roche, Brazil; Roche, Belarus; Roche, Canada; Roche, Chile; Roche, Colombia; Roche, Denmark; Roche, Ecuador; Roche, Estonia; Roche, Greece; Roche, Hong Kong; Roche, Croatia (Hrvatska); Roche, Israel; Roche, India; Roche, Iran; Roche, South Korea; Roche, Sri Lanka; Roche, Macedonia; Roche, Mexico; Roche, New Zealand; Roche, Oman; Roche, Peru; Roche, Philippines; Roche, Pakistan; Roche, Serbia; Roche, Russian Federation; Roche, Singapore; Roche, Slovenia; Roche, Thailand; Roche, Turkey; Roche, Taiwan; Roche, Ukraine; Roche, United States; Roche, Uruguay; Roche, Venezuela; Roche, South Africa

International Drug Name Search

Glossary

BAN	British Approved Name
DCF	Dénomination Commune Française
IS	Inofficial Synonym
OS	Official Synonym
Rec.INN	Recommended International Nonproprietary Name (World Health Organization)
USAN	United States Adopted Name

Click for further information on drug naming conventions and International Nonproprietary Names.